ELE-101 vs Mebufotenin (5-MeO-DMT)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Major Depressive Disorder

Shared mechanism: 5-HT2A receptor · full Major Depressive Disorder pipeline

ELE-101

Developed by Amandala Neuro Limited and partners

Phase 1/2 in Major Depressive Disordersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Mebufotenin (5-MeO-DMT) · GH001

Developed by GH Research

Phase 2 in Major Depressive Disordersmall molecule
Partial signal

NCT05800860 · Phase 2 · completed

This randomized, quadruple-masked, placebo-controlled phase 2 trial assigned 81 patients with treatment-resistant depression to inhaled GH001 (mebufotenin) or placebo. The registered primary endpoint was the change in MADRS depression score from baseline to Day 7. The sponsor reported a placebo-adjusted reduction of 15.5 points at Day 8 (P<0.0001), so the primary endpoint was met. This result comes from a company filing and is not posted on ClinicalTrials.gov, and no power calculation was found.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

Mean change in MADRS from Baseline to Day 7: Placebo-adjusted MADRS reduction from baseline at Day 8: -15.5 points (LS mean difference -15.5, effect size -2.0, P<0.0001) (met)

Result source: NCT05800860

Results for Major Depressive Disorder

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointELE-101Mebufotenin (5-MeO-DMT)
MADRS, change (acute)—Not reported—Not reported
CGI-S, change (acute)—Not reported—Not reported
MADRS response—Not reported—Not reported
MADRS remission—Not reported—Not reported
Relapse (% of patients)—Not reported—Not reported

MADRS, change (acute)

ELE-101
—Not reported
Mebufotenin (5-MeO-DMT)
—Not reported

CGI-S, change (acute)

ELE-101
—Not reported
Mebufotenin (5-MeO-DMT)
—Not reported

MADRS response

ELE-101
—Not reported
Mebufotenin (5-MeO-DMT)
—Not reported

MADRS remission

ELE-101
—Not reported
Mebufotenin (5-MeO-DMT)
—Not reported

Relapse (% of patients)

ELE-101
—Not reported
Mebufotenin (5-MeO-DMT)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ELE-101: no structured comparison results are available for Major Depressive Disorder.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Mebufotenin (5-MeO-DMT)

MADRS -15.5 score @ 1.142857wk
absolute change · score
No placebo or comparator arm
NCT05800860 · Phase 2 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ELE-101's landscape · Mebufotenin (5-MeO-DMT)'s landscape